Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostatin plus radiotherapy followed by nivolumab maintenance in advanced NSCLC (post-second-line)
ChiCTR2300072347Phase 4Recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of endostar and nivolumab in non-small cell lung cancer (NSCLC), sponsored by Beijing Chest Hospital. Primary endpoint: Objective response rate. Started Jun 2023; status: recruiting.
02
Drugs
endostarnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300072347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072347.